Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Publication of abstract on isophosphoramide mustard in hematology journal announced
December 29th, 2005
Ziopharm Oncology, Inc. (OTC BB: ZIOP) announced the publication of an abstract on ZIO-201, a stabilized form of isophosphoramide mustard (IPM), currently under investigation for use in advanced cancers. The preclinical abstract is published in Blood, the official journal of the American Society of Hematology. In abstract 4727 titled "Isophosphoramide Mustard-lysine (ZIO-201): Active Moiety of Ifosfamide (IFOS) without Kidney Toxicity," by Mary Taub and co-workers at the State University of New York at Buffalo, data regarding effects on rabbit kidney proximal tubule cells report ZIO-201 avoids kidney damage caused by metabolites of ifosfamide, the pro-drug of...
Source: Blood Weekly (2005-12-29)
|
